{"uid":"cap_7hICcd2r5Y4ahMx9FdXHv","slug":"icc-2022-pmf-diagnostic-criteria-calculator-arber-2022-866e9c4f","name":"ICC 2022 PMF Diagnostic Criteria Calculator (Arber 2022)","description":"ICC 2022 prefibrotic and overt PMF (Arber 2022). Diagnosed iff 3 majors and ≥1 minor. Majors: megakaryocyte morphology, not another myeloid neoplasm, JAK2/CALR/MPL or other clone or no reactive fibrosis. Minors: anemia not from comorbidity, WBC ≥11e9/L, splenomegaly, LDH above ULN; leukoerythroblastosis counts only in overt PMF. Not DIPSS, MIPSS70, WHO 5th, or post-PV/post-ET MF. magent does not read fibrosis grade or sequence drivers. Not a diagnosis or medical device.","url":"https://api.magentlab.com/api/calc/icc_pmf","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"headers":{"type":"object","additionalProperties":{"type":"string"}},"queryParams":{"type":"object","required":["phenotype","megakaryocyte_morphology","not_other_myeloid","clonal_or_no_reactive","anemia_not_comorbid","leukocytosis_ge_11","splenomegaly","ldh_above_uln","leukoerythroblastosis"],"properties":{"phenotype":{"enum":["pre","overt"],"type":"string","description":"pre (prefibrotic/early PMF) or overt (overt fibrotic PMF) as assigned by the caller (Arber 2022 ICC). Required. magent does not assign phenotype from a biopsy."},"splenomegaly":{"type":"boolean","description":"Palpable splenomegaly as assigned by the caller (Arber 2022 ICC PMF minor). true or false. magent does not examine the spleen."},"ldh_above_uln":{"type":"boolean","description":"LDH above the institutional upper limit of normal as assigned by the caller (Arber 2022 ICC PMF minor). true or false. magent does not assay LDH."},"not_other_myeloid":{"type":"boolean","description":"Does not meet ICC/WHO criteria for BCR::ABL1-positive CML, PV, ET, MDS, or another defined myeloid neoplasm, as assigned by the caller (Arber 2022 ICC PMF major). true or false. magent does not diagnose those neoplasms."},"leukocytosis_ge_11":{"type":"boolean","description":"Leukocytosis ≥11 × 10^9/L as assigned by the caller (Arber 2022 ICC PMF minor). true or false. magent does not assay WBC."},"anemia_not_comorbid":{"type":"boolean","description":"Anemia not attributed to a comorbid condition, as assigned by the caller (Arber 2022 ICC PMF minor). true or false. magent does not assay hemoglobin."},"clonal_or_no_reactive":{"type":"boolean","description":"JAK2, CALR, or MPL mutation, or another clonal marker, or absence of reactive bone-marrow fibrosis, as assigned by the caller (Arber 2022 ICC PMF major). true or false. magent does not sequence."},"leukoerythroblastosis":{"type":"boolean","description":"Leukoerythroblastosis as assigned by the caller (Arber 2022 ICC overt-PMF minor). Counts toward minor_count only when phenotype is overt; echoed but not counted when phenotype is pre. true or false. magent does not read a smear."},"megakaryocyte_morphology":{"type":"boolean","description":"Megakaryocytic proliferation and atypia for the chosen phenotype, as assigned by the caller (Arber 2022 ICC PMF major). For pre: without reticulin fibrosis grade >1, with increased age-adjusted cellularity, granulocytic proliferation, and often decreased erythropoiesis. For overt: accompanied by reticulin and/or collagen fibrosis grade 2 or 3. true or false. magent does not read a biopsy."}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}},"responseSchema":null,"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.005","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.005/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_c6V5AtCsVXhgcMYCo4fMu","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.005","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Evaluates whether a patient meets ICC 2022 (Arber 2022) diagnostic criteria for prefibrotic or overt primary myelofibrosis by checking 3 major and ≥1 minor criteria.","exampleAgentPrompt":"My patient has abnormal megakaryocyte morphology, is JAK2-positive, doesn't meet criteria for any other myeloid neoplasm, and on overt PMF phenotype — they also have splenomegaly and LDH above the upper limit of normal, no anemia from comorbidity, no leukocytosis, and no leukoerythroblastosis. Do they meet ICC 2022 (Arber 2022) criteria for PMF?","exampleUseCases":[{"title":"Prefibrotic PMF workup in clinic","prompt":"I have a patient I've classified as prefibrotic PMF — megakaryocyte morphology is characteristic, JAK2 mutation present, no other myeloid neoplasm diagnosis, and they have anemia that isn't from any comorbidity and an elevated LDH. No splenomegaly, no leukocytosis. Do they satisfy ICC 2022 Arber prefibrotic PMF criteria?"},{"title":"Overt PMF criteria check with leukoerythroblastosis","prompt":"Patient is phenotyped as overt PMF: megakaryocyte morphology abnormal, CALR mutation confirmed, not another myeloid neoplasm, and they have leukoerythroblastosis on peripheral smear plus splenomegaly. No anemia or leukocytosis independently noted. Can you run the ICC 2022 Arber 2022 overt PMF diagnostic checklist?"},{"title":"Ruling in or out PMF for MPL-positive patient","prompt":"We have an MPL-mutated patient with no other identifiable myeloid neoplasm and characteristic megakaryocyte morphology — phenotype is prefibrotic. Their only minor criterion is WBC ≥11×10⁹/L. Do they meet the ICC 2022 PMF diagnostic threshold under Arber 2022?"}],"resultDescription":"Returns whether the patient meets ICC 2022 (Arber 2022) PMF diagnostic criteria (diagnosed or not), along with which major and minor criteria were satisfied and the total counts, for either prefibrotic or overt PMF phenotype.","failureModes":["Missing required query parameters returns a validation error","Invalid enum value for phenotype (not 'pre' or 'overt') causes rejection","Boolean fields provided as strings instead of booleans may fail schema validation","Caller-assigned inputs that contradict clinical reality (e.g., leukoerythroblastosis counted for prefibrotic) may yield unexpected output since the API follows ICC rules per phenotype","No result if network/payment (x402) fails"],"whenToPreferThis":"Use this endpoint when you need to programmatically apply the ICC 2022 (Arber 2022) primary myelofibrosis diagnostic criteria to a set of caller-assigned clinical flags. Prefer it over manual checklists or other scoring tools when building hematology decision-support workflows, automating chart review, or auditing PMF diagnoses for consistency. Not suitable for DIPSS/MIPSS70 prognostication, WHO 5th edition criteria, or post-PV/post-ET MF evaluation.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T07:01:25.035Z","isFirstParty":false}